We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 2,560

Medical devices and 3D printing
  • Taylor Wessing
  • European Union, United Kingdom
  • September 30 2013

3D printing is an exciting technology that is developing rapidly. While high performance industrial systems can cost between £10,000 and £700,000

Repercussions expected on medicine advertising campaign
  • Olivares
  • Mexico
  • December 2 2009

A bold new television advertising and publicity campaign was launched recently by a pharmaceutical company called Genoma Lab

New government bill in Sweden on the Protection of International Humanitarian Symbols etc
  • Roschier
  • Sweden
  • April 22 2014

The Swedish Government has through a recent government bill (Prop. 201314:129) proposed that a new act on the Protection of International

Intellectual property issues of biomedical outsourcing in the PRC
  • King & Wood Mallesons
  • China
  • September 12 2012

As a result of the development of the biomedical industry and the Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) business models, China has become one of the most important outsourcing destination countries, acquiring considerable market share of the global outsourcing market

Counterfeit drugs
  • Fasken Martineau DuMoulin LLP
  • Africa
  • December 4 2012

Over 80 million dollars' worth of counterfeit pharmaceuticals were seized over a three-day period last July in several African ports at the close of an international customs operation

National case law
  • Cuatrecasas Gonçalves Pereira
  • Portugal
  • February 28 2013

The Judgment n. º 22013 of the Constitutional Court ruled unconstitutional the rule of no. 5 of article 188 of the Medicinal Products Act, the

Overview of pharmaceuticals regulatory environment in the Russian Federation
  • Hogan Lovells
  • Russia
  • March 17 2008

The Russian Federation is an increasingly important market for pharmaceuticals

FTC sues Cephalon over settlement to delay generic entry
  • Squire Patton Boggs
  • USA
  • March 20 2008

The FTC has filed suit against Philadelphia-based pharmaceutical company Cephalon, Inc. for entering into agreements with four generic drug makers to delay entry of generic versions of its sleep disorder drug, Provigil

Federal Court rejects all allegations of invalidity and grants prohibition order to Pfizer
  • Norton Rose Fulbright Canada LLP
  • Canada
  • December 18 2009

On December 18, 2009, the Federal Court granted an application by Pfizer Canada Inc. and Pharmacia Aktieblolag (“Pfizer et al”) for an order prohibiting the Minister of Health from issuing a notice of compliance to Pharmascience Inc. (“PMS”) in respect of a generic version of XALATAN until the expiry of Canadian Patent No. 1,339,132 (“132 patent”

Another case pried from the Eastern District of Texas: Federal Circuit grants third mandamus petition in a year
  • Foley & Lardner LLP
  • USA
  • December 21 2009

In early December 2009, the Court of Appeals for the Federal Circuit again granted a petition for mandamus to transfer a case out of the U.S. District Court for the Eastern District of Texas